Ketorolac Tromethamine Injection, Solution
Product Images NDC 0404-9996

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Ketorolac Tromethamine (NDC 0404-9996). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Henry Schein, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula1.jpg (Formula1)

Chemical structure of Ketorolac tromethamine displaying its molecular composition with defined aromatic and functional groups as part of the injection solution formulation.*

FDA Label Image

Image1.jpg (Image1)

Table presenting approximate average pharmacokinetic parameters (mean ± SD) of Ketorolac Tromethamine following oral, intramuscular, and intravenous bolus doses at various strengths (10 mg to 60 mg). Parameters include bioavailability, Tmax, Cmax (single and steady state), Cmin, Cavg, and volume of distribution (Vβ). The table compares values for oral, intramuscular, and intravenous administration routes.*

FDA Label Image

Image2.jpg (Image2)

A data table presenting pharmacokinetic parameters related to dosing and plasma concentrations, including percent dose metabolized, excreted in feces and urine, plasma protein binding, and derived plasma concentration measures from different pharmacokinetic studies in volunteers, with explanatory footnotes for each measurement.*

FDA Label Image

Image3.jpg (Image3)

A data table titled 'The Influence of Age, Liver and Kidney Function, on the Clearance and Terminal Half-life of Ketorolac Tromethamine (Intramuscular and Oral) in Adult Populations.' It presents total clearance (L/h/kg) and terminal half-life (hours) of ketorolac tromethamine for different subject groups, including normal subjects, healthy elderly, patients with hepatic dysfunction, renal impairment, and renal dialysis patients, showing intramuscular and oral mean values and ranges.*

FDA Label Image

Image4.jpg (Image4)

A data table listing various gastrointestinal and other adverse experiences associated with the product. It includes symptoms such as abdominal pain, constipation/diarrhea, dyspepsia, heartburn, nausea, vomiting, anemia, dizziness, drowsiness, edema, headaches, hypertension, injection site pain, pruritus, purpura, rashes, tinnitus, sweating, and others related to gastrointestinal function and systemic effects.*

FDA Label Image

Image5.jpg (Image5)

A data table titled 'Incidence of Clinically Serious G.I. Bleeding as Related to Age, Total Daily Dose, and History of G.I. Perforation, Ulcer, Bleeding (PUB) after up to 5 Days of Treatment with Ketorolac Tromethamine Injection.' It shows percentages of serious gastrointestinal bleeding by age group (<65 and ≥65 years) and total daily dose categories for adult patients both with and without a history of PUB.*

FDA Label Image

Label1.jpg (Label1)

Label for Ketorolac tromethamine injection, USP, 30 mg/mL in a 1 mL single-dose vial. The label specifies intramuscular or intravenous use only and includes storage instructions at 20 to 25°C. Labeler information shows Henry Schein, Inc., located in Bastian, VA, with product NDC 0404-9996-01. Additional manufacturer details and barcode are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.